Regenerative Medicine

About HemostOD

HemostOD is pioneering the ex vivo manufacturing of engineered, universal platelets to address critical unmet needs in transfusion medicine and targeted drug delivery. Its core technology involves creating an immortalized megakaryocyte cell line and using a microfluidic bioreactor to produce scalable, high-quality platelets. The company has secured seed funding and grants, established key partnerships, and is advancing multiple preclinical programs toward clinical development.

Therapeutic Areas